AngioDynamics, Inc.
ANGOAngioDynamics, Inc. in brief
AngioDynamics, Inc. is a listed company in the Medical Instruments industry, based in Latham, New York, USA. It was founded in 1988. Its market value was $512 M on 27 October 2026, which makes it the 12,451st largest listed company in the world and the 2,514th largest in the USA on this site. In the year to May 2026 it had sales of $320 M and a net loss of $37 M. It employs about 800 people and Eric Honroth is its chief executive. Its largest product and service lines by sales in 2026 were Med Device (53%) and Med Tech (47%). By market, the largest shares of its 2026 sales came from USA (86%). Its shares trade under the symbol ANGO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About AngioDynamics, Inc.
AngioDynamics is a Global provider of Industry Medical Devices company used around the world for the treatment of cancer and peripheral vascular disease. The headquarters is in USA.
Angiodynamics company annual revenue was 338 million USD and annual net loss was -52 million USD as on May-2022.
AngioDynamics, Inc. timeline
- 1988
- 🏁· approximateFounded
- 2004
- 🔔· approximateInitial public offering on Nasdaq
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- 💰Record revenue of $339 millionFY2022, the highest of the 8 years on record.
Events of AngioDynamics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,336 (Jan 2020) · #2,680 (Jan 2021) · #2,634 (Jan 2022) · #2,571 (Dec 2022) · #3,073 (Jul 2023) · #2,896 (Jan 2024) · #1,298 (Mar 2026) · #2,361 (Aug 2026) · #2,517 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.6×
- Price / book
- 3.0×
- Free cash flow yield
- 0.1%
- Net margin (TTM)
- -10.1%
- Operating margin
- -12.5%
- Return on equity
- -19.3%
- Liabilities / assets
- 36.1%
- Net debt
- $-76M
- Revenue growth
- +9.5%
- R&D / revenue
- 9.2%
- Revenue per employee
- $400 K
- Profit per employee
- $-46 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| May 2026 | $320M | +9.5% | $-40M | $-37M | -11.5% |
| May 2025 | $293M | -3.8% | $-40M | $-34M | -11.6% |
| May 2024 | $304M | -10.3% | $-192M | $-184M | -60.7% |
| May 2023 | $339M | +7.1% | $-51M | $-52M | -15.5% |
| May 2022 | $316M | +8.7% | $-28M | $-27M | -8.4% |
| May 2021 | $291M | +10.2% | $-35M | $-32M | -10.8% |
| May 2020 | $264M | -2.4% | $-167M | $-167M | -63.1% |
| May 2019 | $271M | — | $-9M | $61M | 22.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| May 2026 | $3M | $3M | $1M | $-0.88 | — |
| May 2025 | $-10M | $4M | $-15M | $-0.83 | — |
| May 2024 | $-28M | $3M | $-31M | $-4.59 | — |
| May 2023 | $0M | $4M | $-4M | $-1.33 | — |
| May 2022 | $-7M | $4M | $-11M | $-0.68 | — |
| May 2021 | $24M | $5M | $19M | $-0.82 | — |
| May 2020 | $-15M | $7M | $-22M | $-4.39 | — |
| May 2019 | $37M | $3M | $34M | $1.64 | — |
Quarterly results
Latest quarter to Aug 2026: revenue $81M (+6.9% on a year earlier), net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Aug 2026.
SEC filings
- Oct 8, 202610-QQuarterly report · period to Aug 2026
- Oct 8, 2026DEF 14AProxy statement
- Oct 8, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 8, 20268-KCurrent reportMaterial agreement · Directors or officers changed
- Sep 29, 202610-K/AAnnual report (amended) · period to May 2026
- Sep 29, 202610-K/AAnnual report (amended) · period to May 2026
- Jul 14, 202610-KAnnual report · period to May 2026
- Jul 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Apr 23, 20268-KCurrent reportOther events
- Apr 2, 202610-QQuarterly report · period to Feb 2026
- Apr 2, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Feb 3, 20268-KCurrent reportDirectors or officers changed
Official filings of AngioDynamics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $320 M
- Operating income
- $-40 M
- Net income
- $-37 M
For year ending May-2026 · source: SEC filing
Balance sheet
- Total assets
- $267 M
- Total liabilities
- $96 M
- Total equity
- $171 M
As of May-2026
Top 100 institutional investors in AngioDynamics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 4,048,928 | +245,696 (+6.46%) | 9.63% | $62 M | Nov 13, 2026 |
| 2 | Systematic Financial Management LP | 2,604,656 | -35,558 (-1.35%) | 6.19% | $40 M | Nov 16, 2026 |
| 3 | Royce & Associates LP | 1,921,526 | -48,309 (-2.45%) | 4.57% | $30 M | Nov 9, 2026 |
| 4 | Broadfin Holdings LLC | 1,758,949 | -59,584 (-3.28%) | 4.18% | $27 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 1,712,073 | +17,357 (+1.02%) | 4.07% | $26 M | Nov 13, 2026 |
| 6 | Armistice Capital, LLC | 1,536,000 | -662,000 (-30.12%) | 3.65% | $24 M | Nov 16, 2026 |
| 7 | Weber Capital Management LLC /adv | 1,349,902 | -6,700 (-0.49%) | 3.21% | $21 M | Oct 19, 2026 |
| 8 | Two Sigma Investments, LP | 1,276,984 | +970,724 (+316.96%) | 3.04% | $20 M | Nov 16, 2026 |
| 9 | Arrowstreet Capital, Limited Partnership | 1,031,130 | +338,596 (+48.89%) | 2.45% | $16 M | Nov 13, 2026 |
| 10 | Geode Capital Management, LLC | 1,014,694 | -5,964 (-0.58%) | 2.41% | $16 M | Nov 6, 2026 |
| 11 | State Street Corp | 990,160 | +31,993 (+3.34%) | 2.35% | $15 M | Nov 12, 2026 |
| 12 | Point72 Asset Management, L.P. | 964,953 | -2,097,564 (-68.49%) | 2.29% | $15 M | Nov 16, 2026 |
| 13 | Dimensional Fund Advisors LP | 949,285 | -20,212 (-2.08%) | 2.26% | $15 M | Nov 4, 2026 |
| 14 | Segall Bryant & Hamill, LLC | 897,065 | -29,646 (-3.20%) | 2.13% | $14 M | Nov 16, 2026 |
| 15 | Nuveen, LLC | 884,564 | -314,794 (-26.25%) | 2.10% | $14 M | Nov 10, 2026 |
| 16 | Pier Capital, LLC | 795,961 | -10,717 (-1.33%) | 1.89% | $12 M | Nov 13, 2026 |
| 17 | Goldman Sachs Group Inc | 707,338 | +324,421 (+84.72%) | 1.68% | $11 M | Nov 16, 2026 |
| 18 | AQR Capital Management LLC | 679,522 | +90,365 (+15.34%) | 1.62% | $10 M | Nov 16, 2026 |
| 19 | Acadian Asset Management LLC | 670,159 | +181,898 (+37.25%) | 1.59% | $10 M | Nov 9, 2026 |
| 20 | Renaissance Technologies LLC | 620,383 | -113,500 (-15.47%) | 1.48% | $10 M | Nov 12, 2026 |
| 21 | Marshall Wace, LLP | 605,234 | +184,856 (+43.97%) | 1.44% | $9 M | Nov 13, 2026 |
| 22 | Jacobs Levy Equity Management, Inc | 591,402 | +372,178 (+169.77%) | 1.41% | $9 M | Nov 16, 2026 |
| 23 | Millennium Management LLC | 522,226 | -260,899 (-33.32%) | 1.24% | $8 M | Nov 16, 2026 |
| 24 | Divisadero Street Capital Management, LP | 500,130 | New | 1.19% | $8 M | Nov 16, 2026 |
| 25 | Vanguard Portfolio Management LLC | 445,949 | +5,105 (+1.16%) | 1.06% | $7 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Morgan Stanley | 395,247 | +136,933 (+53.01%) | 0.94% | $6 M | Nov 13, 2026 |
| 27 | Charles Schwab Investment Management Inc | 376,341 | +2,312 (+0.62%) | 0.89% | $6 M | Nov 16, 2026 |
| 28 | Panagora Asset Management Inc | 364,872 | +106,303 (+41.11%) | 0.87% | $6 M | Nov 12, 2026 |
| 29 | First Eagle Investment Management, LLC | 354,435 | -198,435 (-35.89%) | 0.84% | $5 M | Nov 10, 2026 |
| 30 | Northern Trust Corp | 317,328 | -12,399 (-3.76%) | 0.75% | $5 M | Nov 16, 2026 |
| 31 | Bastion Asset Management Inc. | 304,437 | -618,833 (-67.03%) | 0.72% | $5 M | Nov 5, 2026 |
| 32 | Jpmorgan Chase & Co | 288,919 | +68,144 (+30.87%) | 0.69% | $4 M | Nov 12, 2026 |
| 33 | Orion Porfolio Solutions, LLC | 263,710 | +77,866 (+41.90%) | 0.63% | $4 M | Nov 12, 2026 |
| 34 | Vanguard Fiduciary Trust Co | 256,474 | -20,441 (-7.38%) | 0.61% | $4 M | Nov 13, 2026 |
| 35 | Manatuck Hill Partners, LLC | 218,200 | -58,300 (-21.08%) | 0.52% | $3 M | Nov 16, 2026 |
| 36 | SEI Investments Co | 196,165 | +78,896 (+67.28%) | 0.47% | $3 M | Nov 10, 2026 |
| 37 | Kennedy Capital Management LLC | 188,836 | -4,090 (-2.12%) | 0.45% | $3 M | Nov 13, 2026 |
| 38 | Invesco Ltd. | 185,994 | +88,150 (+90.09%) | 0.44% | $3 M | Nov 12, 2026 |
| 39 | D. E. Shaw & Co., Inc. | 185,280 | New | 0.44% | $3 M | Nov 16, 2026 |
| 40 | Bank Of America Corp /de/ | 174,167 | -170,976 (-49.54%) | 0.41% | $3 M | Nov 16, 2026 |
| 41 | UBS Group AG | 173,085 | +88,898 (+105.60%) | 0.41% | $3 M | Nov 10, 2026 |
| 42 | Ameriprise Financial Inc | 163,378 | +63,976 (+64.36%) | 0.39% | $3 M | Nov 16, 2026 |
| 43 | White Pine Capital LLC | 145,476 | +1,012 (+0.70%) | 0.35% | $2 M | Nov 9, 2026 |
| 44 | Bank of New York Mellon Corp | 124,844 | +394 (+0.32%) | 0.30% | $2 M | Nov 5, 2026 |
| 45 | Y-Intercept (Hong Kong) Ltd | 124,596 | +78,328 (+169.29%) | 0.30% | $2 M | Oct 16, 2026 |
| 46 | FMR LLC | 124,458 | +19,942 (+19.08%) | 0.30% | $2 M | Nov 10, 2026 |
| 47 | Paradigm Capital Management Inc/ny | 119,400 | -551,800 (-82.21%) | 0.28% | $2 M | Nov 13, 2026 |
| 48 | Moore Capital Management, LP | 118,466 | -64,633 (-35.30%) | 0.28% | $2 M | Nov 16, 2026 |
| 49 | Walleye Capital LLC | 114,525 | New | 0.27% | $2 M | Nov 13, 2026 |
| 50 | Globeflex Capital L P | 104,155 | 0 (0.00%) | 0.25% | $2 M | Nov 16, 2026 |
| 51 | American Century Companies Inc | 98,338 | -200 (-0.20%) | 0.23% | $2 M | Nov 12, 2026 |
| 52 | Franklin Templeton Inc | 92,677 | +68,474 (+282.92%) | 0.22% | $1 M | Nov 12, 2026 |
| 53 | Natixis | 92,500 | New | 0.22% | $1 M | Nov 6, 2026 |
| 54 | Trexquant Investment LP | 90,148 | +57,945 (+179.94%) | 0.21% | $1 M | Nov 16, 2026 |
| 55 | Qube Research & Technologies Ltd | 89,389 | New | 0.21% | $1 M | Nov 13, 2026 |
| 56 | Informed Momentum Co LLC | 87,098 | New | 0.21% | $1 M | Nov 16, 2026 |
| 57 | Russell Investments Group, Ltd. | 75,085 | +4,895 (+6.97%) | 0.18% | $1 M | Nov 6, 2026 |
| 58 | Royal Bank Of Canada | 72,911 | +537 (+0.74%) | 0.17% | $1 M | Nov 16, 2026 |
| 59 | Quantinno Capital Management LP | 70,880 | +8,170 (+13.03%) | 0.17% | $1 M | Nov 13, 2026 |
| 60 | Connor, Clark & Lunn Investment Management Ltd. | 70,717 | -50,556 (-41.69%) | 0.17% | $1 M | Nov 10, 2026 |
| 61 | Citadel Advisors LLC | 67,392 | +54,908 (+439.83%) | 0.16% | $1 M | Nov 16, 2026 |
| 62 | Mitsubishi UFJ Asset Management Co., Ltd. | 66,387 | +2,658 (+4.17%) | 0.16% | $1 M | Nov 5, 2026 |
| 63 | Price T Rowe Associates Inc /MD/ | 64,098 | 0 (0.00%) | 0.15% | $1 M | Nov 16, 2026 |
| 64 | Strs Ohio | 62,900 | +12,100 (+23.82%) | 0.15% | $1 M | Oct 30, 2026 |
| 65 | Occudo Quantitative Strategies LP | 62,824 | New | 0.15% | $1 M | Nov 16, 2026 |
| 66 | ExodusPoint Capital Management, LP | 62,767 | +31,493 (+100.70%) | 0.15% | $1 M | Nov 16, 2026 |
| 67 | XTX Topco Ltd | 61,857 | +20,827 (+50.76%) | 0.15% | $1 M | Nov 16, 2026 |
| 68 | Jane Street Group, LLC | 60,847 | New | 0.14% | $1 M | Nov 12, 2026 |
| 69 | Envestnet Asset Management Inc | 54,313 | -741 (-1.35%) | 0.13% | $1 M | Nov 16, 2026 |
| 70 | Prudential Financial Inc | 53,323 | +41,837 (+364.24%) | 0.13% | $1 M | Nov 16, 2026 |
| 71 | HSBC Holdings PLC | 52,133 | +24,607 (+89.40%) | 0.12% | $1 M | Nov 16, 2026 |
| 72 | Atria Investments, Inc | 48,344 | +3,136 (+6.94%) | 0.12% | $1 M | Oct 15, 2026 |
| 73 | Moody National Bank Trust Division | 47,927 | 0 (0.00%) | 0.11% | $1 M | Oct 6, 2026 |
| 74 | Rhumbline Advisers | 47,776 | -1,933 (-3.89%) | 0.11% | $1 M | Nov 10, 2026 |
| 75 | Squarepoint Ops LLC | 45,320 | +7,694 (+20.45%) | 0.11% | $1 M | Nov 9, 2026 |
| 76 | Gallagher Fiduciary Advisors, LLC | 45,113 | -135 (-0.30%) | 0.11% | $1 M | Nov 16, 2026 |
| 77 | Boothbay Fund Management, LLC | 45,019 | New | 0.11% | $1 M | Nov 16, 2026 |
| 78 | Barclays PLC | 42,932 | +10,473 (+32.27%) | 0.10% | $1 M | Nov 6, 2026 |
| 79 | StoneX Group Inc. | 41,339 | -2,222 (-5.10%) | 0.10% | $1 M | Nov 3, 2026 |
| 80 | Alliancebernstein L.P. | 40,567 | 0 (0.00%) | 0.10% | $1 M | Nov 16, 2026 |
| 81 | Susquehanna International Group, LLP | 33,432 | +22,785 (+214.00%) | 0.08% | $1 M | Nov 16, 2026 |
| 82 | Canada Pension Plan Investment Board | 32,900 | 0 (0.00%) | 0.08% | $1 M | Nov 16, 2026 |
| 83 | Mariner, LLC | 32,692 | +5,966 (+22.32%) | 0.08% | $1 M | Nov 12, 2026 |
| 84 | Vanguard Global Advisers, LLC | 31,933 | +14,515 (+83.33%) | 0.08% | $0 M | Nov 13, 2026 |
| 85 | Deutsche Bank AG\ | 31,930 | -4,606 (-12.61%) | 0.08% | $0 M | Nov 6, 2026 |
| 86 | Ieq Capital, LLC | 31,746 | +4,678 (+17.28%) | 0.08% | $0 M | Nov 10, 2026 |
| 87 | Susquehanna Portfolio Strategies, LLC | 29,944 | New | 0.07% | $0 M | Nov 16, 2026 |
| 88 | Mercer Global Advisors Inc /adv | 28,421 | +6,327 (+28.64%) | 0.07% | $0 M | Nov 16, 2026 |
| 89 | Assenagon Asset Management S.A. | 27,727 | -27,727 (-50.00%) | 0.07% | $0 M | Oct 15, 2026 |
| 90 | Cerity Partners LLC | 24,242 | +5,778 (+31.29%) | 0.06% | $0 M | Nov 13, 2026 |
| 91 | Great Lakes Advisors, LLC | 22,382 | New | 0.05% | $0 M | Nov 6, 2026 |
| 92 | MetLife Investment Management, LLC | 21,488 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 93 | Engineers Gate Manager LP | 21,386 | New | 0.05% | $0 M | Nov 16, 2026 |
| 94 | Wealth Effects LLC | 20,750 | +3,400 (+19.60%) | 0.05% | $0 M | Oct 23, 2026 |
| 95 | Fox Run Management, L.L.C. | 20,702 | -11,787 (-36.28%) | 0.05% | $0 M | Nov 12, 2026 |
| 96 | Aquatic Capital Management LLC | 20,563 | -7,498 (-26.72%) | 0.05% | $0 M | Nov 16, 2026 |
| 97 | Martingale Asset Management L P | 19,741 | New | 0.05% | $0 M | Nov 12, 2026 |
| 98 | HRT Financial LP | 18,589 | New | 0.04% | $0 M | Nov 13, 2026 |
| 99 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 17,770 | +632 (+3.69%) | 0.04% | $0 M | Nov 16, 2026 |
| 100 | Public Employees Retirement System Of Ohio | 17,670 | +12,720 (+256.97%) | 0.04% | $0 M | Nov 16, 2026 |
Mutual funds holding AngioDynamics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.17 M | $15 M | 2.8% | <0.01% | −3.1% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 973,144 | $13 M | 2.3% | 0.02% | +5.7% | Jun 30, 2026 |
| 🇺🇸 Royce Small-Cap Opportunity FundRoyce & Associates, LP | 707,398 | $9 M | 1.7% | 0.65% | +11% | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 626,469 | $8 M | 1.5% | <0.01% | −16% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 484,796 | $6 M | 1.2% | <0.01% | +2.6% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 406,661 | $6 M | 0.97% | 0.02% | +9.6% | Jul 31, 2026 |
| 🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC | 382,490 | $6 M | 0.91% | 0.14% | −1.9% | Jul 31, 2026 |
| 🇺🇸 First Eagle Small Cap Opportunity FundFirst Eagle Investment Management, LLC | 310,729 | $5 M | 0.74% | 0.16% | +30% | Jul 31, 2026 |
| 🇸🇪 SEB Nordamerikafond SmåbolagSEB Funds AB | 310,537 | $4 M | 0.74% | 1.4% | +6.2% | Jun 30, 2026 |
| 🇺🇸 Royce Micro-Cap Trust, Inc.Royce & Associates, LP | 283,939 | $4 M | 0.68% | 0.41% | +60% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 261,136 | $3 M | 0.62% | 0.02% | +4.2% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 183,958 | $3 M | 0.44% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SBH Small Cap Value FundSEGALL BRYANT AND HAMILL LLC | 205,492 | $3 M | 0.49% | 0.60% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 224,372 | $3 M | 0.53% | 0.05% | −1.3% | May 29, 2026 |
| 🇺🇸 Paradigm Micro-Cap FundPARADIGM FUNDS ADVISOR LLC | 197,900 | $3 M | 0.47% | 1.4% | −18% | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Medical Devices ETFBlackRock Fund Advisors | 193,491 | $3 M | 0.46% | 0.08% | +9.2% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 214,612 | $2 M | 0.51% | <0.01% | −0.9% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 203,599 | $2 M | 0.48% | 0.01% | +3.4% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 192,158 | $2 M | 0.46% | 0.01% | −1.4% | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 143,620 | $2 M | 0.34% | 0.03% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 137,468 | $2 M | 0.33% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Royce Micro-Cap FundRoyce & Associates, LP | 140,402 | $2 M | 0.33% | 0.43% | +68% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 130,994 | $2 M | 0.31% | 0.13% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 110,473 | $2 M | 0.26% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 125,123 | $2 M | 0.30% | 0.11% | +33% | Jun 30, 2026 |
| 🇺🇸 Adara Smaller Companies FundRBB Fund, Inc. | 141,441 | $2 M | 0.34% | 0.20% | +2.5% | May 31, 2026 |
| 🇺🇸 Transamerica Small/Mid Cap ValueTransamerica Asset Management, Inc. | 104,350 | $2 M | 0.25% | 0.24% | −9.3% | Jul 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 124,182 | $1 M | 0.30% | <0.01% | +1.0% | May 31, 2026 |
| 🇺🇸 Variable Portfolio - Partners Small Cap Value FundColumbia Management Investment Advisers, LLC | 103,495 | $1 M | 0.25% | 0.30% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 90,400 | $1 M | 0.21% | 0.02% | +9.8% | Jul 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 97,802 | $1 M | 0.23% | 0.02% | +11% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 85,678 | $1 M | 0.20% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Transamerica Small/Mid Cap Value VPTransamerica Asset Management, Inc. | 92,250 | $1 M | 0.22% | 0.21% | −7.8% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 83,883 | $1 M | 0.20% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 83,274 | $1 M | 0.20% | <0.01% | +2.3% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 90,394 | $1 M | 0.21% | 0.04% | −0.1% | May 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 68,308 | $1 M | 0.16% | 0.04% | −9.3% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 62,748 | $1 M | 0.15% | 0.09% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 70,651 | $1 M | 0.17% | 0.02% | +15% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 75,964 | $1 M | 0.18% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P. | 54,970 | $1 M | 0.13% | 0.06% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 54,321 | $1 M | 0.13% | <0.01% | +20% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P Health Care Equipment ETFSSGA Funds Management, Inc. | 61,173 | $1 M | 0.15% | 0.53% | −34% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 49,233 | $1 M | 0.12% | 0.02% | +14% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 63,002 | $1 M | 0.15% | <0.01% | +5.7% | May 31, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 57,598 | $1 M | 0.14% | 0.07% | +10% | May 31, 2026 |
| 🇺🇸 Transamerica Small Cap ValueTransamerica Asset Management, Inc. | 43,000 | $1 M | 0.10% | 0.56% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Multifactor ETFThe Vanguard Group, Inc. | 50,141 | $1 M | 0.12% | 0.09% | no change | May 31, 2026 |
| 🇺🇸 Royce Capital Fund - Micro-Cap PortfolioRoyce & Associates, LP | 44,184 | $1 M | 0.11% | 0.41% | — | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 40,624 | $1 M | 0.10% | 0.01% | −1.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 39,911 | $1 M | 0.09% | 0.02% | +10% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Equity FundCharles Schwab Investment Management, Inc. | 34,907 | $1 M | 0.08% | 0.08% | new | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 31,851 | $0 M | 0.08% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SIMT Tax-Managed Small/Mid Cap FundSEI Institutional Managed Trust | 34,707 | $0 M | 0.08% | 0.06% | −20% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 32,983 | $0 M | 0.08% | 0.13% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 27,445 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 35,214 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 25,360 | $0 M | 0.06% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 22,195 | $0 M | 0.05% | <0.01% | +7.7% | Jul 31, 2026 |
| 🇺🇸 Venerable US Small Cap FundVenerable Investment Advisers, LLC | 24,203 | $0 M | 0.06% | 0.19% | +4.4% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 23,792 | $0 M | 0.06% | 0.01% | −14% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 22,891 | $0 M | 0.05% | <0.01% | +88% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 22,762 | $0 M | 0.05% | 0.01% | −24% | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 19,026 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 23,467 | $0 M | 0.06% | 0.02% | +5.1% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 23,038 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 17,796 | $0 M | 0.04% | 0.02% | +9.5% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 20,026 | $0 M | 0.05% | <0.01% | −9.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 22,290 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 19,201 | $0 M | 0.05% | 0.02% | +5.0% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR US Small Cap Low Volatility Index ETFSSGA Funds Management, Inc. | 19,044 | $0 M | 0.05% | 0.10% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard U.S. Multifactor FundThe Vanguard Group, Inc. | 21,328 | $0 M | 0.05% | 0.09% | no change | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 15,193 | $0 M | 0.04% | <0.01% | +3.2% | Jul 31, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 14,917 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 16,851 | $0 M | 0.04% | <0.01% | −20% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 16,083 | $0 M | 0.04% | 0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 13,297 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 13,079 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 12,435 | $0 M | 0.03% | 0.01% | −0.2% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 12,374 | $0 M | 0.03% | 0.01% | +62% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 10,769 | $0 M | 0.03% | <0.01% | +61% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 10,633 | $0 M | 0.03% | 0.02% | −18% | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 11,540 | $0 M | 0.03% | <0.01% | −2.5% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 9,874 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 10,544 | $0 M | 0.03% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 10,259 | $0 M | 0.02% | <0.01% | −0.7% | Jun 30, 2026 |
| 🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc. | 9,521 | $0 M | 0.02% | 0.02% | −44% | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 10,763 | $0 M | 0.03% | 0.07% | — | Mar 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 8,350 | $0 M | 0.02% | 0.05% | +24% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 8,259 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard U.S. Quality Factor ETFThe Vanguard Group, Inc. | 9,180 | $0 M | 0.02% | 0.02% | new | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 8,019 | $0 M | 0.02% | <0.01% | +27% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 7,824 | $0 M | 0.02% | 0.02% | +13% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 7,690 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 8,570 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 6,228 | $0 M | 0.01% | 0.02% | −0.1% | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 6,128 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 7,675 | $0 M | 0.02% | <0.01% | −5.1% | May 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 6,406 | $0 M | 0.02% | 0.02% | −4.6% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 5,298 | $0 M | 0.01% | <0.01% | +61% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at AngioDynamics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Eric HonrothPresident and CEO, Director | Grant or award | +62,928 | — | — | 62,928 | Form 4 |
| filed | Eric HonrothPresident and CEO, Director | Grant or award | +38,265 | — | — | 101,193 | Form 4 |
| filed | Stephen A. TrowbridgeEVP and CFO | Sell | -23,615 | $12.27 | $290 K | 280,461 | Form 4 |
| filed | Stephen A. TrowbridgeEVP and CFO | Sell | -1,720 | $12.17 | $21 K | 304,076 | Form 4 |
| filed | Warren Nighan Jr.SVP Quality and Regulatory | Sell | -23,370 | $14.72 | $344 K | 64,745 | Form 4 |
| filed | Stephen A. TrowbridgeEVP and CFO | Option exercise | +16,296 | — | — | 314,115 | Form 4 |
| filed | Warren Nighan Jr.SVP Quality and Regulatory | Option exercise | +5,694 | — | — | 89,786 | Form 4 |
| filed | Laura PiccininiSVP International | Option exercise | +8,047 | — | — | 86,435 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: AngioDynamics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q2 2026 | Q4 2026 | $0M |
| Q1 2026 | Q3 2026 | $0M |
| Q4 2025 | Q2 2026 | $0M |
| Q3 2025 | Q1 2026 | $0M |
| Q2 2025 | Q4 2025 | $0M |
| Q1 2025 | Q3 2025 | $0M |
| Q4 2024 | Q2 2025 | $1.1M |
| Q3 2024 | Q1 2025 | $0.6M |
| Q2 2024 | Q4 2025 | $0M |
| Q1 2024 | Q3 2025 | $0M |
| Q4 2023 | Q2 2025 | $0M |
| Q3 2023 | Q1 2025 | $0M |
| Q2 2018 | Q4 2018 | $0M |
| Q1 2018 | Q3 2018 | $0M |
| Q2 2017 | Q4 2017 | $5.7M |
| Q1 2017 | Q3 2017 | $0M |
Fails to deliver
- : 8,620 shares at $12.17
- : 136 shares at $15.47
- : 992 shares at $15.77
- : 26 shares at $15.82
- : 1,363 shares at $15.67
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
AngioDynamics, Inc. scorecard#
Passes 7 of the 21 checks that could be worked out: strongest in financial health (2 of 3), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 27, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median3.0×Price to book 3.0× against Medical Instruments's median of 3.9×.
- ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Medical Instruments's median of 3.0×.
- ✗Free cash flow yield above 5%0.1%Free cash flow is 0.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✓Revenue grew in the newest year9.5%Revenue up 9.5% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-1.9%-1.9% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-1.9%-1.9% a year against Medical Instruments's median of 5.0% (37 companies).
- ✗Earnings per share grew in the newest year-0.88 vs -0.83Diluted EPS -0.88 in fiscal 2025 against -0.83 the year before (report's currency).
- ✗Net income higher than five years earlier-$37 M-$37 M in fiscal 2025 against -$32 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$37 MNet income -$37 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-12.5%-12.5% against Medical Instruments's median of 7.2% (46 companies).
- ✗Return on equity above 15%-20.8%-20.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-12.5%-12.5% in fiscal 2025 against -15.1% in 2022.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities2.2×Current ratio 2.19 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone1.85Z-score 1.85 (grey zone) for fiscal 2025.
Shareholder returns1 of 2
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.6%Diluted shares up 1.6% in fiscal 2025.
- ✗Dividends and buybacks above 3% of the market value0.0%Dividends and buybacks were 0.0% of the market value.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from AngioDynamics, Inc.'s statements, beside the median of Medical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -12.5% | 7.2% | |
| Net margin | -11.5% | 3.8% | |
| Return on equity | -20.8% | 3.5% | |
| Revenue growth, 3 years a year | -1.9% | 5.0% | |
| Revenue growth | 9.5% | 8.9% | |
| Free cash flow margin | 0.2% | 6.3% |
4of 8on the Piotroski tests of financial strength
- Net loss of $37 million, the 7th loss-making year in a row.
AngioDynamics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to May 31, 2026 | FY 2024to May 31, 2025 | FY 2023to May 31, 2024 | FY 2022to May 31, 2023 | FY 2021to May 31, 2022 | FY 2020to May 31, 2021 | FY 2019to May 31, 2020 | FY 2018to May 31, 2019 | FY 2017to May 31, 2018 | FY 2016to May 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 320+9.5%100% | 292−3.8%100% | 304−10.3%100% | 339+7.1%100% | 316+8.7%100% | 291+10.2%100% | 264−2.4%100% | 271+3.4%100% | 262r344−3.0%100% | 270r350—100% | |
| Cost of revenue | 145+7.8%45.4% | 135−9.7%46.1% | 149−9.3%49.1% | 165+9.3%48.6% | 150+12.1%47.6% | 134+17.9%46.1% | 114−0.7%43.1% | 115−2.7%42.4% | 118r167−6.4%45.0% | 126r173—46.6% | |
| Gross profit | 175+10.9%54.6% | 158+1.9%53.9% | 155−11.2%50.9% | 174+5.1%51.4% | 166+5.7%52.4% | 157+4.3%53.9% | 150−3.7%56.9% | 156+8.4%57.6% | 144r177−0.1%55.0% | 144r176—53.4% | |
| Research and development | 29+12.3%9.2% | 26−16.8%9.0% | 32+5.5%10.4% | 30−2.8%8.8% | 31−15.5%9.7% | 36+22.6%12.5% | 30+5.0%11.2% | 28+16.1%10.4% | 24r25+0.8%9.3% | 24r25—9.0% | |
| Selling and marketing | 113+10.0%35.4% | 103+0.3%35.3% | 103−1.4%33.8% | 104+9.4%30.8% | 95+17.2%30.1% | 81+3.4%27.9% | 79+2.3%29.8% | 77+5.1%28.4% | 73r77−2.3%27.9% | 75r79—27.7% | |
| General and administrative | 44+3.8%13.6% | 42+2.3%14.4% | 41+2.9%13.5% | 40+4.0%11.8% | 38+7.1%12.2% | 36−5.2%12.3% | 38+8.5%14.3% | 35+12.6%12.9% | 31r31−0.5%11.8% | 31r31—11.5% | |
| Operating expenses | 215+8.7%67.1% | 198−50.8%67.6% | 402+78.2%132% | 225+16.1%66.5% | 194+1.1%61.4% | 192−39.5%66.0% | 317+91.9%120% | 165+4.7%61.1% | 158r166+1.9%60.4% | 155r163—57.5% | |
| Operating income | −40—−12.5% | −40—−13.7% | −192—−63.3% | −51—−15.1% | −28—−9.0% | −35—−12.1% | −167—−63.3% | −9.4—−3.5% | −14r11—−5.4% | −11r13—−4.1% | |
| Interest expense and finance costs | — | — | −1.6−160%−0.5% | 2.7+293%0.8% | 0.7−20.1%0.2% | 0.9−5.1%0.3% | 0.9−82.2%0.3% | 5.1+66.5%1.9% | 3.1+7.9%1.2% | 2.8—1.1% | |
| Other non-operating income (expense) | 3.9−20.6%1.2% | 4.9—1.7% | −0.8—−0.3% | −0.6—−0.2% | −0.8−959%−0.2% | 0.1—0.0% | −0.1r−1.0—−0.0% | −0.2r−5.3—−0.1% | −3.1—−1.2% | −3.1—−1.2% | |
| Income before tax | −36—−11.3% | −34—−11.6% | −192—−63.1% | −54—−16.1% | −30—−9.5% | −36—−12.4% | −168—−63.6% | −15—−5.4% | −17r7.5—−6.6% | −14r9.8—−5.3% | |
| Income tax | 0.4—0.1% | −0.0—−0.0% | −7.3—−2.4% | −2.0—−0.6% | −3.4—−1.1% | −4.5—−1.5% | −1.3—−0.5% | −3.6—−1.3% | −11r−8.9—−4.2% | −7.2r4.8—−2.7% | |
| Income from continuing operations | — | — | — | — | — | −32—−10.8% | −167—−63.1% | −11—−4.1% | −6.2—−2.4% | −7.1—−2.6% | |
| Income from discontinued operations | — | — | — | — | — | 0—0.0% | 0−100%0.0% | 72+221%26.8% | 23+87.1%8.6% | 12—4.5% | |
| Net income attributable to shareholders | −37—−11.5% | −34—−11.6% | −184r−184—−60.7% | −52r−52—−15.5% | −27—−8.4% | −32r−32—−10.8% | −167−372%−63.1% | 61+276%22.7% | 16+226%6.2% | 5.0—1.9% | |
| Earnings per share, basic | -0.88—— | -0.83—— | -4.59—— | -1.33—— | -0.68—— | -0.82—— | -4.39−368%— | 1.64+273%— | 0.44+214%— | 0.14—— | |
| Earnings per share, diluted | -0.88—— | -0.83—— | -4.59—— | -1.33—— | -0.68—— | -0.82—— | -4.39−368%— | 1.64+273%— | 0.44+214%— | 0.14—— | |
| Shares, weighted average (basic) | 42+1.6%— | 41+1.7%— | 40+1.8%— | 39+1.2%— | 39+1.7%— | 38+1.0%— | 38+1.3%— | 37+1.1%— | 37+1.3%— | 37—— | |
| Shares, weighted average (diluted) | 42+1.6%— | 41+1.7%— | 40+1.8%— | 39+1.2%— | 39+1.7%— | 38+1.0%— | 38+1.3%— | 37+1.1%— | 37r38+1.3%— | 37r37—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 54−3.6%20.2% | 56−26.5%20.0% | 76+70.5%23.9% | 45+54.8%8.4% | 29−40.1%5.2% | 48−11.5%8.6% | 54−76.1%9.2% | 228+207%27.2% | 74+55.8%10.5% | 48—6.7% | |
| Short-term investments | — | — | — | — | — | — | — | 0−100%0.0% | 1.3+8.4%0.2% | 1.2—0.2% | |
| Receivables | 48+12.7%18.1% | 43−1.7%15.3% | 44−17.4%13.7% | 53+1.0%9.9% | 52+47.7%9.5% | 35+13.2%6.3% | 31−28.3%5.3% | 44+10.6%5.2% | 39−11.5%5.6% | 45—6.3% | |
| Inventory | 52−15.4%19.6% | 62+2.3%22.1% | 61+9.6%19.1% | 55+7.7%10.4% | 51+5.7%9.3% | 49−18.8%8.7% | 60+49.5%10.1% | 40+2.0%4.8% | 39r49−27.9%5.6% | 55—7.7% | |
| Other current assets | 8.8+16.4%3.3% | 7.5−41.9%2.7% | 13+181%4.1% | 4.6−57.3%0.9% | 11+24.4%2.0% | 8.7+19.0%1.5% | 7.3+82.6%1.2% | 4.0−7.0%0.5% | 4.3−29.8%0.6% | 6.1r5.8—0.9% | |
| Current assets | 163−2.9%61.2% | 168−12.9%60.1% | 193+18.2%60.8% | 164+14.1%30.7% | 143+1.8%25.9% | 141−7.9%25.1% | 153−51.5%25.7% | 315+87.6%37.7% | 168+9.2%23.8% | 154—21.7% | |
| Property, plant and equipment | 27−16.1%10.1% | 32−9.4%11.5% | 36−19.6%11.2% | 44−1.4%8.3% | 45+21.4%8.1% | 37+30.9%6.6% | 28+16.7%4.8% | 24−5.7%2.9% | 26r42−43.2%3.6% | 45—6.4% | |
| Right-of-use (leased) assets | 5.1+31.2%1.9% | 3.9−33.7%1.4% | 5.8+13.5%1.8% | 5.1−26.7%1.0% | 7.0−25.7%1.3% | 9.4−7.5%1.7% | 10—1.7% | — | — | — | |
| Goodwill | — | — | 0−100%0.0% | 159−20.8%29.9% | 201−0.1%36.4% | 201+0.4%35.9% | 201−42.3%33.7% | 348+21.6%41.6% | 286r361−20.8%40.5% | 361—51.0% | |
| Other intangible assets | 67−2.8%25.2% | 69−10.7%24.7% | 77−30.4%24.4% | 111−27.1%20.9% | 152−9.8%27.6% | 169−14.3%30.1% | 197+35.6%33.2% | 145+29.2%17.4% | 113r130−22.7%16.0% | 146—20.6% | |
| Total assets | 267−4.6%100% | 280−11.8%100% | 318−40.4%100% | 533−3.6%100% | 553−1.5%100% | 561−5.5%100% | 594−29.0%100% | 836+18.6%100% | 705−0.4%100% | 708—100% | |
| Accounts payable | 32−5.3%11.8% | 33−11.8%11.9% | 38−6.7%11.9% | 40+44.2%7.6% | 28+42.9%5.1% | 20+2.8%3.5% | 19−16.4%3.2% | 23+44.7%2.7% | 16−12.8%2.2% | 18—2.6% | |
| Debt due within a year | — | — | — | — | — | — | 0−100%0.0% | 7.5+50.0%0.9% | 5.00.0%0.7% | 5.0—0.7% | |
| Current liabilities | 75−1.9%28.0% | 76−16.4%27.2% | 91+8.7%28.7% | 84+12.8%15.7% | 74+29.1%13.4% | 58+11.9%10.3% | 51−29.8%8.7% | 73+27.9%8.8% | 57−19.9%8.1% | 72—10.1% | |
| Long-term debt | — | — | — | — | — | — | — | 124+43.6%14.9% | 87−5.1%12.3% | 91—12.9% | |
| Lease liabilities (non-current) | 3.9+83.3%1.4% | 2.1−46.5%0.8% | 3.9+18.8%1.2% | 3.3−29.5%0.6% | 4.7−35.7%0.9% | 7.3−12.3%1.3% | 8.3—1.4% | — | — | — | |
| Total liabilities | 96−0.9%36.1% | 97−13.3%34.7% | 112−27.4%35.3% | 154+20.3%29.0% | 128+5.1%23.2% | 122−12.5%21.7% | 139−37.1%23.4% | 222+36.1%26.5% | 163−15.6%23.1% | 193—27.3% | |
| Retained earnings | −466—−174% | −429—−153% | −395—−124% | −211—−39.6% | −158—−28.7% | −132—−23.5% | −100−251%−16.9% | 66+1196%7.9% | 5.1—0.7% | −11—−1.6% | |
| Shareholders' equity | 171−6.6%63.9% | 183−11.0%65.3% | 206−45.7%64.7% | 378−10.9%71.0% | 424−3.4%76.8% | 439−3.4%78.3% | 455−26.0%76.6% | 615+13.3%73.5% | 543+5.4%76.9% | 515—72.7% | |
| Total liabilities and equity | 267−4.6%100% | 280−11.8%100% | 318−40.4%100% | 533−3.6%100% | 553−1.5%100% | 561−5.5%100% | 594−29.0%100% | 836+18.6%100% | 705−0.4%100% | 708—100% | |
| Shares outstanding | 42+1.7%— | 41+1.4%— | 40+2.1%— | 40+1.1%— | 39+1.6%— | 39+1.2%— | 38+1.2%— | 38+1.0%— | 37+1.0%— | 37—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 23−11.0%7.2% | 26−6.9%8.8% | 28−10.2%9.1% | 31+5.2%9.1% | 29+13.2%9.3% | 26+8.9%8.9% | 24−8.0%9.0% | 26+11.7%9.6% | 23−6.6%8.9% | 25—9.2% | |
| Share-based compensation | 14+42.9%4.4% | 9.8−7.2%3.3% | 11−5.6%3.5% | 11+4.4%3.3% | 11+24.0%3.4% | 8.6+13.6%3.0% | 7.6−17.9%2.9% | 9.2+16.9%3.4% | 7.9+28.0%3.0% | 6.2—2.3% | |
| Cash from operating activities | 3.1—1.0% | −10—−3.5% | −28−36200%−9.3% | 0.1—0.0% | −7.2−130%−2.3% | 24—8.3% | −15−139%−5.5% | 37−9.3%13.8% | 41−25.9%15.8% | 56—20.7% | |
| Capital expenditure | −2.6—−0.8% | −4.5—−1.5% | −2.5—−0.8% | −3.8—−1.1% | −4.3—−1.4% | −5.2—−1.8% | −7.2—−2.7% | −3.1—−1.2% | −2.4—−0.9% | −3.0—−1.1% | |
| Cash from investing activities | −5.9—−1.9% | −10−108%−3.5% | 124—40.7% | −9.7—−2.9% | −19—−6.1% | −14—−4.7% | −63−177%−24.0% | 83—30.5% | −3.7—−1.4% | −2.6—−0.9% | |
| Debt issued | — | — | — | — | — | — | — | 0—0.0% | 0−100%0.0% | 116—43.2% | |
| Debt repaid | 0—0.0% | 0—0.0% | −50—−16.5% | −45—−13.3% | 0—0.0% | −20—−6.9% | −133—−50.2% | −15—−5.5% | −5.0—−1.9% | −140—−52.0% | |
| Shares bought back | 0—0.0% | −1.7—−0.6% | 0—0.0% | 0—0.0% | — | — | — | 0—0.0% | 0—0.0% | −14—−5.0% | |
| Cash from financing activities | 0.6—0.2% | −0.3—−0.1% | −64−353%−21.1% | 25+231%7.5% | 7.7—2.4% | −17—−5.8% | −95−381%−36.1% | 34—12.5% | −12—−4.4% | −38—−14.1% | |
| Exchange-rate effect on cash | 0.3−32.9%0.1% | 0.4+218%0.1% | 0.1+191%0.0% | 0.0—0.0% | −0.5−257%−0.2% | 0.3—0.1% | −0.1—−0.0% | −0.4−181%−0.1% | 0.5—0.2% | 0—0.0% | |
| Change in cash | −2.0—−0.6% | −20−164%−6.9% | 31+99.0%10.3% | 16—4.7% | −19—−6.1% | −6.3—−2.2% | −173−213%−65.6% | 154+478%56.7% | 27+74.6%10.1% | 15—5.6% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Aug 31, 2026 | Q1 FY2026to Aug 31, 2026 | Q4 FY2025to May 31, 2026 | Q3 FY2025to Feb 28, 2026 | Q2 FY2025to Nov 30, 2025 | Q1 FY2025to Aug 31, 2025 | Q4 FY2024to May 31, 2025 | Q3 FY2024to Feb 28, 2025 | Q2 FY2024to Nov 30, 2024 | Q1 FY2024to Aug 31, 2024 | Q4 FY2023to May 31, 2024 | Q3 FY2023to Feb 29, 2024 | Q2 FY2023to Nov 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 325+8.2%100% | 81+6.9%100% | 87*+8.0%100% | 78+8.9%100% | 79+9.0%100% | 76+12.2%100% | 80*+12.9%100% | 72−4.2%100% | 73−7.9%100% | 67—100% | 71*—100% | 75—100% | 79—100% | |
| Cost of revenue | 144+4.7%44.3% | 33−2.9%40.6% | 40*+5.0%46.0% | 37+11.5%47.1% | 35+5.2%43.6% | 34+10.0%44.7% | 38*+16.9%47.3% | 33−15.7%46.0% | 33−15.1%45.2% | 31—45.6% | 32*—45.7% | 39—52.3% | 39—49.1% | |
| Gross profit | 181+11.2%55.7% | 48+14.8%59.4% | 47*+10.8%54.0% | 41+6.7%52.9% | 45+12.2%56.4% | 42+14.0%55.3% | 42*+9.6%52.7% | 39+8.4%54.0% | 40−0.9%54.8% | 37—54.4% | 39*—54.3% | 36—47.7% | 40—50.9% | |
| Research and development | 31+17.7%9.5% | 8.0+24.3%9.9% | 8.2*+24.1%9.4% | 7.1+2.5%9.0% | 7.8+20.7%9.8% | 6.4+2.1%8.5% | 6.6*−2.0%8.2% | 6.9−15.6%9.6% | 6.4−25.7%8.8% | 6.3—9.3% | 6.7*—9.5% | 8.2—10.9% | 8.7—10.9% | |
| Selling and marketing | 115+9.1%35.4% | 30+6.6%37.1% | 31*+17.7%35.9% | 27+7.6%35.0% | 27+4.4%33.6% | 28+9.9%37.2% | 26*+7.6%33.0% | 26+0.4%35.4% | 26+0.5%35.1% | 26—37.9% | 25*—34.6% | 25—33.8% | 25—32.2% | |
| General and administrative | 44−0.2%13.4% | 12−0.7%15.4% | 10*+0.3%11.9% | 11+2.2%13.7% | 10−2.3%12.8% | 13+14.4%16.6% | 10*−2.0%12.8% | 10−0.8%14.6% | 10+11.9%14.3% | 11—16.3% | 10*—14.7% | 11—14.1% | 9.3—11.7% | |
| Operating expenses | 218+8.6%66.9% | 55+5.4%68.4% | 57*+18.7%65.8% | 54+11.5%69.4% | 51−0.2%64.1% | 53+5.4%69.4% | 48*−9.4%59.9% | 49−79.9%67.8% | 51−4.5%70.0% | 50—73.8% | 53*—74.6% | 242—322% | 53—67.5% | |
| Operating income | −37—−11.2% | −7.3—−9.0% | −10*—−11.8% | −13—−16.5% | −6.1—−7.7% | −11—−14.1% | −5.8*—−7.2% | −10.0—−13.9% | −11—−15.2% | −13—−19.4% | −14*—−20.4% | −200—−266% | −13—−16.6% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | — | — | −0.4—−0.5% | −0.5—−0.7% | |
| Other non-operating income (expense) | 3.9−26.1%1.2% | 0.0—0.0% | −0.7*—−0.8% | 4.9−12.3%6.2% | −0.2−193%−0.3% | −0.2−142%−0.2% | −0.3*—−0.4% | 5.6+3467%7.7% | 0.2−51.0%0.3% | 0.4—0.6% | −0.3*—−0.4% | 0.2—0.2% | 0.5—0.6% | |
| Income before tax | −33—−10.1% | −7.3—−9.0% | −11*—−12.7% | −8.1—−10.3% | −6.4—−8.0% | −11—−14.3% | −6.1*—−7.6% | −4.4—−6.1% | −11—−14.9% | −13—−18.8% | −14*—−19.9% | −200—−266% | −13—−16.0% | |
| Income tax | 0.2—0.1% | −0.2−406%−0.2% | 0.4*—0.4% | 0.0—0.0% | −0.0—−0.0% | 0.1−51.1%0.1% | −0.1*—−0.1% | −0.0—−0.0% | −0.1−101%−0.2% | 0.1—0.2% | −0.7*—−1.0% | −12—−16.0% | 16—20.8% | |
| Net income attributable to shareholders | −33—−10.1% | −7.1—−8.8% | −11*—−13.2% | −8.1—−10.3% | −6.4—−8.0% | −11—−14.4% | −6.1*—−7.5% | −4.4—−6.1% | −11—−14.7% | −13—−19.0% | −13r−13*—−18.9% | −188—−250% | −29—−36.7% | |
| Earnings per share, basic | — | -0.17—— | — | -0.19—— | -0.15—— | -0.26—— | — | -0.11—— | -0.26—— | -0.31—— | — | -4.67—— | -0.72—— | |
| Earnings per share, diluted | — | -0.17—— | — | -0.19—— | -0.15—— | -0.26—— | — | -0.11—— | -0.26—— | -0.31—— | — | -4.67—— | -0.72—— | |
| Shares, weighted average (basic) | 42+2.1%— | 42+2.1%— | — | 42+1.8%— | 42+1.5%— | 41+1.3%— | — | 41+1.5%— | 41+1.7%— | 41—— | — | 40—— | 40—— | |
| Shares, weighted average (diluted) | 42+2.1%— | 42+2.1%— | — | 42+1.8%— | 42+1.5%— | 41+1.3%— | — | 41+1.5%— | 41+1.7%— | 41—— | — | 40—— | 40—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 34—14.0% | 34−12.4%14.0% | 54−3.6%20.2% | 38−15.5%14.5% | 42−23.0%15.4% | 39−29.5%14.6% | 56−26.5%20.0% | 45−42.9%15.7% | 54−11.2%18.6% | 55—18.7% | 76—23.9% | 78—24.2% | 61—12.2% | |
| Receivables | 45—18.6% | 45+5.3%18.6% | 48+12.7%18.1% | 46+4.8%17.5% | 44+3.0%16.5% | 43+7.8%16.1% | 43−1.7%15.3% | 43−12.1%15.2% | 43−16.4%14.8% | 40—13.5% | 44—13.7% | 49—15.2% | 52—10.3% | |
| Inventory | 55—22.7% | 55−11.7%22.7% | 52−15.4%19.6% | 59−7.2%22.5% | 66−0.5%24.3% | 62−3.8%23.4% | 62+2.3%22.1% | 63+8.7%22.1% | 66+2.6%22.6% | 65—22.0% | 61—19.1% | 58—17.9% | 64—12.9% | |
| Other current assets | 9.2—3.8% | 9.2−29.4%3.8% | 8.8+16.4%3.3% | 14−11.8%5.2% | 9.7−20.4%3.6% | 13−2.5%4.9% | 7.5−41.9%2.7% | 15+41.5%5.4% | 12+39.9%4.2% | 13—4.5% | 13—4.1% | 11—3.4% | 8.7—1.7% | |
| Current assets | 143—59.1% | 143−8.7%59.1% | 163−2.9%61.2% | 156−9.7%59.7% | 161−8.0%59.8% | 157−9.2%59.0% | 168−12.9%60.1% | 172−12.5%60.4% | 175−5.4%60.1% | 173—58.8% | 193—60.8% | 197—60.6% | 185—37.1% | |
| Property, plant and equipment | 28—11.5% | 28−10.7%11.5% | 27−16.1%10.1% | 29−10.4%11.2% | 31−7.4%11.3% | 31−9.6%11.7% | 32−9.4%11.5% | 33−12.2%11.4% | 33−22.5%11.3% | 34—11.7% | 36—11.2% | 37—11.4% | 43—8.5% | |
| Right-of-use (leased) assets | 4.9—2.0% | 4.9+44.2%2.0% | 5.1+31.2%1.9% | 5.4+25.9%2.1% | 5.7+19.2%2.1% | 3.4−35.8%1.3% | 3.9−33.7%1.4% | 4.3+11.5%1.5% | 4.8+17.0%1.6% | 5.3—1.8% | 5.8—1.8% | 3.9—1.2% | 4.1—0.8% | |
| Goodwill | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 159—31.9% | |
| Other intangible assets | 62—25.6% | 62−9.5%25.6% | 67−2.8%25.2% | 65−7.7%25.1% | 67−8.7%24.7% | 68−9.8%25.7% | 69−10.7%24.7% | 71−13.0%24.9% | 73−29.6%25.1% | 76—25.8% | 77—24.4% | 82—25.1% | 104—20.8% | |
| Total assets | 242—100% | 242−8.9%100% | 267−4.6%100% | 261−8.7%100% | 270−7.5%100% | 266−9.5%100% | 280−11.8%100% | 285−12.1%100% | 292−41.6%100% | 294—100% | 318—100% | 325—100% | 500—100% | |
| Accounts payable | 27—11.0% | 27−16.6%11.0% | 32−5.3%11.8% | 29−3.8%11.2% | 35+1.9%13.1% | 32+2.0%12.0% | 33−11.8%11.9% | 30−13.9%10.6% | 35−7.7%11.9% | 31—10.7% | 38—11.9% | 35—10.8% | 38—7.5% | |
| Current liabilities | 60—24.7% | 60−12.6%24.7% | 75−1.9%28.0% | 66−15.3%25.3% | 72−18.8%26.7% | 68−11.0%25.7% | 76−16.4%27.2% | 78−9.2%27.3% | 89+13.5%30.4% | 77—26.1% | 91—28.7% | 86—26.4% | 78—15.6% | |
| Lease liabilities (non-current) | 3.6—1.5% | 3.6+111%1.5% | 3.9+83.3%1.4% | 4.2+62.6%1.6% | 4.5+47.8%1.7% | 1.7−50.6%0.6% | 2.1−46.5%0.8% | 2.6+10.7%0.9% | 3.0+18.0%1.0% | 3.5—1.2% | 3.9—1.2% | 2.3—0.7% | 2.6—0.5% | |
| Total liabilities | 78—32.2% | 78−10.2%32.2% | 96−0.9%36.1% | 87−12.3%33.5% | 93−10.9%34.6% | 87−10.6%32.7% | 97−13.3%34.7% | 100−6.2%34.9% | 105+6.5%35.9% | 97—33.1% | 112—35.3% | 106—32.7% | 98—19.7% | |
| Retained earnings | −473—−196% | −473—−196% | −466—−174% | −455—−174% | −446—−166% | −440—−166% | −429—−153% | −423—−148% | −419—−144% | −408—−139% | −395—−124% | −382—−118% | −194—−38.8% | |
| Shareholders' equity | 164—67.8% | 164−8.3%67.8% | 171−6.6%63.9% | 173−6.7%66.5% | 176−5.6%65.4% | 179−9.0%67.3% | 183−11.0%65.3% | 186−15.0%65.1% | 187−53.5%64.1% | 197—66.9% | 206—64.7% | 219—67.3% | 401—80.3% | |
| Total liabilities and equity | 242—100% | 242−8.9%100% | 267−4.6%100% | 261−8.7%100% | 270−7.5%100% | 266−9.5%100% | 280−11.8%100% | 285−12.1%100% | 292−41.6%100% | 294—100% | 318—100% | 325—100% | 500—100% | |
| Shares outstanding | 42—— | 42+2.4%— | 42+1.7%— | 42+1.7%— | 42+1.8%— | 41+1.1%— | 41+1.4%— | 41+1.4%— | 41+1.5%— | 41—— | 40—— | 40—— | 40—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 23−9.9%6.9% | 5.5−7.6%6.8% | 5.6*−4.0%6.5% | 5.6*−11.5%7.1% | 5.8r5.7*−15.2%7.3% | 6.0r6.0−12.3%7.9% | 5.8*−14.4%7.3% | 6.3*−16.0%8.8% | 6.9*+2.7%9.4% | 6.8—10.1% | 6.8*—9.6% | 7.5*—10.0% | 6.7*—8.5% | |
| Share-based compensation | 14+27.3%4.3% | 4.5+0.7%5.6% | 3.9*+139%4.5% | 2.7+12.5%3.4% | 2.9+16.0%3.7% | 4.5+39.5%5.9% | 1.6*−13.4%2.0% | 2.4−7.7%3.3% | 2.5+31.6%3.4% | 3.2—4.7% | 1.9*—2.7% | 2.6—3.5% | 1.9—2.4% | |
| Cash from operating activities | 3.7—1.1% | −15—−18.9% | 17*−7.2%20.2% | −3.1*—−4.0% | 4.7*+88.5%5.9% | −16—−21.0% | 19*+276%23.5% | −13*—−18.3% | 2.5*−53.0%3.4% | −18—−27.0% | 5.0*—7.0% | −13*—−16.7% | 5.3*—6.7% | |
| Capital expenditure | −2.2—−0.7% | −0.4—−0.5% | −0.4*—−0.5% | −1.0*—−1.3% | −0.4*—−0.5% | −0.7—−1.0% | −0.8*—−1.0% | −1.8*—−2.5% | −0.8*—−1.1% | −1.1—−1.6% | −0.6*—−0.8% | −0.6*—−0.8% | −0.6*—−0.7% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | — | — | — | −3.3*—−4.3% | — | |
| Cash from investing activities | −7.5—−2.3% | −3.1—−3.9% | −1.3*—−1.5% | −1.5*—−1.9% | −1.6*—−2.0% | −1.6—−2.0% | −2.6*—−3.3% | −3.2*−111%−4.4% | −2.0*—−2.7% | −2.4—−3.6% | −2.3*—−3.3% | 29*—39.1% | −1.8*—−2.3% | |
| Debt issued | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | |
| Debt repaid | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | |
| Shares bought back | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | −1.1*—−1.5% | −0.6—−0.8% | 0*—0.0% | 0*—0.0% | 0*—0.0% | |
| Cash from financing activities | −1.0−340%−0.3% | −1.4−1062%−1.7% | −0.1*—−0.1% | 0.6*−91.3%0.8% | −0.1*—−0.1% | 0.1—0.2% | −5.8*—−7.2% | 7.1*+930%9.9% | −1.1*—−1.5% | −0.5—−0.8% | −5.0*—−7.0% | 0.7*—0.9% | −0.4*—−0.4% | |
| Exchange-rate effect on cash | 0.0−92.0%0.0% | −0.0−120%−0.0% | −0.0*−103%−0.0% | 0.2*—0.2% | −0.1*—−0.1% | 0.2+64.7%0.3% | 0.7*—0.9% | −0.1*—−0.2% | −0.3*−261%−0.4% | 0.1—0.2% | −0.1*—−0.1% | −0.0*—−0.0% | 0.2*—0.2% | |
| Change in cash | −4.8—−1.5% | −20—−24.6% | 16*+44.2%18.5% | −3.8*—−4.9% | 2.9*—3.6% | −17—−22.6% | 11*—13.9% | −9.3*−153%−13.0% | −0.9*−128%−1.3% | −21—−31.2% | −2.4*—−3.4% | 18*—23.4% | 3.3*—4.2% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Aug 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What AngioDynamics, Inc. sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Med Device$170 M53%+2.6%
- Med Tech$150 M47%+18%
Business segments
- Med Device$170 M53%+2.6%
- Med Tech$150 M47%+18%
Countries and regions
- 🇺🇸 USA$275 M86%+9.5%
- International(total)$45 M14%+9.0%
Source: SEC annual report (XBRL data) · as of May 31, 2026
Where AngioDynamics, Inc. operates: 8 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 8 subsidiaries on file.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at AngioDynamics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2026Mr. Clemmer | $6.1 M | $13.7 M | $1.8 M | $50 (peers $57) |
| 2025Mr. Clemmer | $5.5 M | $6.8 M | $1.5 M | $44 (peers $43) |
| 2024Mr. Clemmer | $5.0 M | $971 K | $1.3 M | $27 (peers $43) |
| 2023Mr. Clemmer | $4.0 M | −$2.1 M | $914 K | $41 (peers $56) |
| 2022Mr. Clemmer | $5.7 M | $5.0 M | $1.3 M | $85 (peers $59) |
| 2021Mr. Clemmer | $4.0 M | $13.9 M | $1.0 M | $226 (peers $124) |
Source: SEC proxy statement (Form DEF 14A) · as of May 31, 2026
Events at AngioDynamics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 3 · New debt 1 · Shareholder vote 2 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Directors and officersMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 8, 2026
H-1B hiring at AngioDynamics, Inc.#
2 labor condition applications certified in fiscal 2023 for 2 positions, at a median wage of $85 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Clinical Affairs SpecialistCompliance Officers | 1 | $86 K |
| Regulatory Affairs Specialist IICompliance Officers | 1 | $85 K |
Where: Marlborough, MA 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2023 | 2 | 2 | $85 K | 3 |
| FY2022 | 1 | 1 | $113 K | 1 |
| FY2020 | 5 | 5 | $80 K | 6 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as ANGIODYNAMICS, INC.
Discuss AngioDynamics, Inc.#
3 automatic updates and 0 member comments. Sign in to comment and react.
- Insider trading in October 2026automatic update · Oct 31, 2026
Directors and officers of AngioDynamics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $310,688 in 2 trades. Awards, option exercises and shares withheld for tax are not counted.
- Results announced on 8 October 2026automatic update · Oct 8, 2026
AngioDynamics, Inc. announced results on 8 October 2026 (SEC Form 8-K, item 2.02). For the quarter ended 31 August 2026: revenue of $81 million (up 7% from a year earlier) and a net loss of $7 million.
- Mutual funds: 158 funds hold $148 millionautomatic update · Jul 31, 2026
158 mutual funds in 2 countries hold shares of AngioDynamics, Inc. worth $148 million, about 26.7% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 66 funds added shares and 43 sold; on balance they bought $4 million. Share splits are not counted as trading.
How AngioDynamics, Inc. compares in Medical Instruments
- Market cap$512 M · higher than 30% of 116
- Revenue$320 M · higher than 40% of 120
- Net margin-10.1% · higher than 13% of 114
- Revenue growth9.5% · higher than 54% of 49
- Price / sales1.6× · lower than 85% of 85
- Price / book3.0× · lower than 55% of 84
- FCF yield0.1% · higher than 42% of 39
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| AngioDynamics, Inc.🇺🇸 | $512 M | — | -10.1% | +9.5% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Visco Vision Inc.$557 M
- SD Biosensor, Inc$563 M
- Zhonghong Pulin Medical Products Co., Ltd.$744 M
- Jins Holdings Inc.$755 M
- Blue Sail Medical Co., Ltd.$773 M
- Menicon Co., Ltd.$814 M
Sources and freshness
- Market cap:
- Oct 27, 2026
- Annual results:
- For year ending May-2026
- Balance sheet:
- As of May-2026
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at AngioDynamics, Inc.? Verify and update this profile — free
Show AngioDynamics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.